FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm
April 11, 2016
The U.S. Food and Drug Administration today approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL.
etc.